CO6910198A2 - Compuestos y métodos para mejorar las respuestas inmunitarias innatas - Google Patents

Compuestos y métodos para mejorar las respuestas inmunitarias innatas

Info

Publication number
CO6910198A2
CO6910198A2 CO14058151A CO14058151A CO6910198A2 CO 6910198 A2 CO6910198 A2 CO 6910198A2 CO 14058151 A CO14058151 A CO 14058151A CO 14058151 A CO14058151 A CO 14058151A CO 6910198 A2 CO6910198 A2 CO 6910198A2
Authority
CO
Colombia
Prior art keywords
compounds
methods
immune responses
innate immune
improve innate
Prior art date
Application number
CO14058151A
Other languages
English (en)
Spanish (es)
Inventor
Anna Banka
Janos Botyanszki
Eric Gregory Burroughs
John George Catalano
Wendy Huang Chern
Hamilton D Dickson
Margaret J Gartland
Robert Hamatake
Hans Hofland
Jesse Daniel Keicher
Christopher Brooks Moore
John Bradford Shotwell
Matthew Tallant
Jean-Philippe Therrien
Shihyun You
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CO6910198A2 publication Critical patent/CO6910198A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO14058151A 2011-10-21 2014-03-18 Compuestos y métodos para mejorar las respuestas inmunitarias innatas CO6910198A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23

Publications (1)

Publication Number Publication Date
CO6910198A2 true CO6910198A2 (es) 2014-03-31

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14058151A CO6910198A2 (es) 2011-10-21 2014-03-18 Compuestos y métodos para mejorar las respuestas inmunitarias innatas

Country Status (23)

Country Link
US (1) US20140249143A1 (https=)
EP (1) EP2768506A4 (https=)
JP (1) JP2014532626A (https=)
KR (1) KR20140094559A (https=)
CN (1) CN103957910A (https=)
AR (1) AR088793A1 (https=)
AU (1) AU2012325971B2 (https=)
BR (1) BR112014008727A2 (https=)
CA (1) CA2851801A1 (https=)
CL (1) CL2014001016A1 (https=)
CO (1) CO6910198A2 (https=)
CR (1) CR20140175A (https=)
DO (1) DOP2014000081A (https=)
EA (1) EA201490610A1 (https=)
IL (1) IL231894A0 (https=)
MX (1) MX2014004814A (https=)
PE (1) PE20141359A1 (https=)
PH (1) PH12014500865A1 (https=)
SG (2) SG10201505664WA (https=)
TW (2) TW201542567A (https=)
UY (1) UY34406A (https=)
WO (1) WO2013059559A2 (https=)
ZA (1) ZA201402392B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US10112895B2 (en) 2014-09-29 2018-10-30 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗b型肝炎ウイルス剤
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
WO2020083662A1 (en) 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
EP4136086A1 (en) 2020-04-14 2023-02-22 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
EP4694881A1 (en) * 2023-04-14 2026-02-18 Humanwell Pharmaceutical US, Inc. Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2026084955A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084957A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084958A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE441449B (sv) * 1979-02-09 1985-10-07 Roussel Uclaf Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ.ホフマン−ラ ロシュ アーゲー イミダゾ縮合化合物
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2416488B1 (en) * 2009-03-31 2019-03-06 Daikin Industries, Ltd. Electrode film for polymer actuator element, and polymer actuator element comprising same
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
CR20140175A (es) 2014-06-03
SG10201505664WA (en) 2015-09-29
PE20141359A1 (es) 2014-10-13
EA201490610A1 (ru) 2014-09-30
TW201333003A (zh) 2013-08-16
PH12014500865A1 (en) 2014-05-26
WO2013059559A3 (en) 2013-11-14
MX2014004814A (es) 2014-05-27
TW201542567A (zh) 2015-11-16
AU2012325971A1 (en) 2014-04-17
CN103957910A (zh) 2014-07-30
BR112014008727A2 (pt) 2017-04-25
US20140249143A1 (en) 2014-09-04
SG11201400988SA (en) 2014-07-30
JP2014532626A (ja) 2014-12-08
DOP2014000081A (es) 2014-07-15
CA2851801A1 (en) 2013-04-25
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
KR20140094559A (ko) 2014-07-30
AR088793A1 (es) 2014-07-10
UY34406A (es) 2013-05-31
IL231894A0 (en) 2014-05-28
AU2012325971B2 (en) 2016-03-31
CL2014001016A1 (es) 2015-01-16
EP2768506A4 (en) 2015-08-19
WO2013059559A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
CO6910198A2 (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
IL291394A (en) Dosing combinations for reducing undesired humoral immune responses
IL283728A (en) Tolerogenic synthetic nanocarriers to reduce antibody responses
CO7020865A2 (es) Microorganismos y métodos para producir alquenos
BR112014006324A2 (pt) método para tratar hcv
BR112013023241A8 (pt) melhorias para entidades biológicas imobilizadas
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
PL2755389T3 (pl) Sposób predykcji inter i urządzenie do niego
BR112013033720A2 (pt) método para tratar eczema
HRP20161064T1 (hr) Piridin-2-amidi korisni kao cb2-agonisti
BR112014013034A2 (pt) método para produzir um anticorpo
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych
BR112014008691A2 (pt) anticorpos para cd1d
CO6870003A2 (es) Vacunas bovinas y métodos
CO6842021A2 (es) Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos
BR112013022254A2 (pt) método e disposição para gerar oxigênio
BR112014000460A8 (pt) método para produzir alimento seco
BR112013023465A2 (pt) método para produzir l-cisteína
IT1403906B1 (it) Apparato e metodo per realizzare sbozzati
CO7010822A2 (es) Método para retardar la recticulación en operación de tratamiento de pozo
BR112013033851A2 (pt) método para formar sevoflurano
BR112012027834A2 (pt) método para produzir macarrão instântaneo e macarrão instântaneo
BR112014005614A2 (pt) método para produzir chocolate, e, chocolate
BR112014003151A2 (pt) métodos para produzir biodiesel
IL231798A0 (en) Method and composition